Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

Clinical trial NCT07011823 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07011823
Sponsor: Gangnam Severance Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple-Negative Breast Neoplasm

Start date: 2025-07-16
Primary completion: 2027-07-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.